A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants with Relapsed / Refractory Multiple Myeloma (DREAMM 6).

  • Spencer, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

StatusActive
Effective start/end date25/02/195/02/21